Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS-1: Ianalumab in Patients with Active Sjögren's Syndrome
2020-005661-14Phase 3Active
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Ianalumab with Placebo (2 arms). Started Apr 2022; status: active.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2020-005661-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005661-14.